Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Post by willibrichon Nov 22, 2010 4:10pm
541 Views
Post# 17741069

Interesting market today !

Interesting market today !With Brownstone closing at .80 , up 57 % on the day on 4.3 million shares and QEI closing at .21 , up 13.5 % on an amazing 17 million shares, it certainly reveals the different natures of BWN versus QEI shareholders.

Could it be that a substantial number of QEI shareholders do not appreciate or understand what they have right now. If 5 feet of pay yields 2225 bopd, then the full 50 feet of the Mirador is going to yield many multiples of this first flow test. And maybe it is an omission, but I gather that they have not even used a pump yet. Just observed open formation flow rates

You know it does not really matter if the final production from the Canaguay # 1 well is 12,000 bopd, 16,000 bopd or 20,000 bopd, QEI will be in the oil business right and proper.

Anything under 30 cents is a screaming buy. Today I sold some of my  silver stocks like RVM. AXR and ASM and bought more QEI.    
Bullboard Posts